The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Lupin’s Luforbec beclometasone dipropionate / formoterol fumarate MDI, a generic version of Chiesi’s Fostair MDI, for the treatment of asthma and COPD, the company said.
Lupin Limited CEO Vinita Gupta said, “We are truly delighted to receive the first marketing authorization for generic Fostair 100/6 µg pMDI in the UK. This is an important milestone for our respiratory franchise as we expand our product offering across the globe. At Lupin, we remain committed to serving patients suffering from respiratory diseases with quality and cost-effective treatment.”
Lupin President, EMEA, Thierry Volle commented, “The approval of Luforbec 100/6 µg pMDI is a pivotal milestone for the UK and a welcome step for Lupin as we draw on our strong expertise in inhalation research and development and expand our respiratory portfolio. We are proud to support healthcare providers and patients by continuing to invest in specialized treatments for chronic diseases.”
Read the Lupin press release.
